We investigated the usefulness of TS-1 for the treatment of @entity135 in 29 @entity1 who received treatment on an outpatient basis at our institution. Among the 29 @entity1 , 22 @entity1 in whom the response was evaluable were included in the efficacy analysis. To assess the safety of TS-1, the severity of adverse events was examined in the 29 @entity1 . Each course of treatment consisted of oral administration of TS-1 at a dose of 80 to 120 mg/day, depending on the body surface area (BSA), for 28 consecutive days, followed by a 14-day rest period. None of the @entity1 showed complete response (CR), 7 showed partial response (PR), 10 showed no change (NC), and 5 showed @entity74 ( @entity74 ). The response rate was thus 31.8%. Severe adverse events (grades 3 and 4) occurred in 2 @entity1 . One developed grade 3 @entity1431 and grade 4 @entity882 . The other developed @entity6715 that was assessed as grade 4. The findings indicate that TS-1 might be useful for the treatment of @entity1 with @entity135 on an outpatient basis without affecting their quality of life (QOL), although careful monitoring is essential to watch for the development of severe adverse events.

[The usefulness of TS-1 for the treatment of XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck carcinoma'] @entity6715 :: ('MESH:D013262', 'Disease') :: ['Stevens-Johnson syndrome'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity74 :: ('MESH:D030342', 'Disease') :: ['PD', 'progressive disease']
@entity135 :: (MESH:D006258,Disease) :: ['head and neck cancer']
